MDCX Medicus Pharma Ltd. Earnings per share growth this year

The success of Medicus Pharma Ltd. (MDCX) relies on clinical test results and regulatory approval for non-invasive skin cancer therapy. The volatility of annual earnings per share confirms this dependency, with its value recorded at 75.80. Optimized component supply chains eliminate logistics disruptions, while unique patents for microneedle patches create a significant defensive barrier within the competitive dermatological niche.

Medicus Pharma Ltd. (MDCX): Earnings growth in current year from 11/15/2024 to 11/15/2026

Financial and market metric breakdowns for Medicus Pharma Ltd (MDCX)

- current quotes and average value forecast:

Market Chart Medicus Pharma Corp|MDCX - Price Target Chart

- market capitalization data:

Market Capitalization Medicus Pharma Ltd.|MDCX - Total Company Value

- book capitalization information:

Accounting Value per Share Medicus Pharma|MDCX - Book Capitalization|Market-to-Book Ratio medicuspharma.com|MDCX - Company Total Assets

- debt and liquidity details:

- net income and valuation ratios data:

MDCX - Net Income|Expected Net Income Medicus Pharma Ltd.|MDCX - Price to Earnings Ratio|Price to Expected Earnings Ratio Medicus Pharma Ltd.|MDCX - PEG Multiple|Business Value to Operating Income Before Depreciation Medicus Pharma|MDCX - Operating profit EBITDA|Net earnings per share (EPS TTM) Medicus Pharma|MDCX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months medicuspharma.com|MDCX - Earnings per share growth in current year|Expected earnings per share growth for next year Medicus Pharma Ltd.

- sales volume and revenue information:

MDCX - Revenue and Sales Volume|Projected Sales Volume Medicus Pharma Ltd.|MDCX - Market Cap to Revenue|Forward Price to Sales Medicus Pharma Ltd.|MDCX - Sales Growth YoY (Last Twelve Months)

Fundamental valuation:MDCX, Medicus Pharma Ltd.

Medicus Pharma Ltd. is developing a high-tech dermatology segment utilizing an innovative microneedle patch system. The commercialization efficiency of this technology is directly reflected in the net income per share dynamics. This indicator measures the percentage deviation of the current EPS from the same period last year. Analyzing the YoY net income per share change ratio allows for the timely identification of a value trap. The positive trend on the chart confirms a fundamental business turnaround.

Key competitors

KRYS - Expected net earnings per share growth this year|Earnings per share growth in current year Apogee Therapeutics, Inc.|Earnings per share growth this year ARQT (Arcutis Biotherapeutics)|Net earnings per share growth this year VCEL (Vericel)|ORKA - Earnings per share growth rate in current year|Earnings growth in current year SMTI (Sanara MedTech, Inc.)|dbv-technologies.com - Earnings per share growth in current year|SLSN - Earnings per share growth in current year|DERM - Earnings growth in current year|FBRX (Forte Biosciences, Inc.) - Net earnings per share growth this year|Empro Group Inc. - Earnings per share increase in current year|SLGL (Sol-Gel Technologies Ltd) - Earnings growth in current year|AXIL: Earnings per share increase in current year|Earnings growth in current year VRCA|Net earnings per one share growth for the current year HOTH|Earnings per share growth in current year biofrontera-us.com BFRI|Earnings per share increase in current year VYNE|SNOA - Earnings per share growth in current year|Earnings per share increase in current year QNRX (quoinpharma.com)|Azitra (AZTR) - Earnings per share growth in current year|DRMA: Net earnings per one share growth for the current year|ELAB (Elevai Labs) - Earnings growth in current year|RVNC: Earnings per share increase in current year